Biohaven and SK Biopharmaceuticals sign global licensing deal
Biohaven and SK Biopharmaceuticals entered into a strategic global licensing agreement for a Kv7 ion channel platform and opakalim for epilepsy.
Story updates
06:53:16 AM UTC
SquawkNews
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.